Emyria quarterly revenue jumps to A$1.42 million in September
Key Facts
Emyria Limited, listed on the Australian market under the ticker EMD, reported revenue of about A$1.42 million in the quarter ended September 30, 2026, compared with about A$0.47 million in the September 2025 quarter. The company described the revenue as a quarterly record in its quarterly activities report, published on October 29, 2026. The company operates in intensive mental health care through its Empax clinic network. Revenue growth came during a period that saw the network expand its locations and investment in operational readiness and clinical staff. However, the company’s report did not directly link the revenue increase to the expansion, so it does not establish that the clinic openings or increased operating capacity were the sole cause of the growth.
The figures included about A$725,000 in earned revenue that had not yet been received in cash, according to the company. This means that this portion of recorded revenue had not become cash held by the company by the time of the report. Cash receipts during the quarter, meanwhile, were about A$1.6 million. The company also recorded net operating cash outflows of about A$2.28 million over the same period. These figures place revenue growth alongside actual cash movement, including receipts, amounts not yet collected in cash and outflows.
Emyria said operating outflows were mainly associated with upfront investment in national operational readiness, clinical capabilities and the required workforce. It added that increased medicine inventory supported preparation for expansion and the opening of the Sydney clinic. In September, the company opened its first clinic in New South Wales, adding Sydney to the Empax network, which now spans four Australian states. The new clinic increased national treatment capacity from 14 to 18 beds. The company estimated that this capacity allows for up to 90 dosing sessions a week, a ceiling for the stated capacity after the opening.
The cash-flow appendix showed that cash and cash equivalents stood at A$7.290 million at the start of the September quarter, then fell to A$4.745 million at its end. The report estimated the available funding period at about 2.08 quarters at the operating cash-flow rate used in that estimate. This puts the operating cash outflows recorded during the quarter in the context of the company’s remaining liquidity at period-end. The company said spending was related to operational and clinical readiness and increased medicine inventory, alongside the opening of the Sydney site. The figures cover the period ended September 30, 2026, while the details were published in the company’s subsequent report.
On demand, the company said it received the first approvals for eligible patients’ treatment applications through Australia’s Department of Veterans’ Affairs after the period ended. It added that Empax centres had received more than 40 referrals from the department by the October 29 report. The company plans to begin the first department-funded treatments for veterans, while increasing patient numbers in Sydney and raising utilisation of the network’s available capacity. These are the workstreams the company announced after opening the clinic and increasing the number of beds. The report did not specify how many treatments had begun or the expected revenue from referrals.
On another commercial front, Emyria said it was in advanced discussions with an international pharmaceutical sponsor. The company expected to provide further information about the discussions during the following quarter if they were completed, without the report giving details of a deal or its value. It also appointed former U.S. Secretary of Veterans Affairs David Shulkin as a strategic adviser to support partnerships and commercial opportunities in the United States. In the context of its regulatory presence there, the company said it participated in a U.S. Food and Drug Administration session on psychedelic drugs on September 14, 2026. The agency selected the company to deliver an in-person presentation at the session, according to the report.
Upcoming operational steps include bringing a second authorised prescriber into the Mornington Peninsula clinic in Victoria during the fourth quarter of calendar year 2026. The company said the additional therapist capacity in Perth is expected to begin having an effect in the first quarter of 2027. This coincides with plans to start treatments funded by the Department of Veterans’ Affairs, grow patient numbers in Sydney and increase utilisation of the Empax network. As for the discussions with the international pharmaceutical sponsor, the company expects to provide further information during the following quarter if they are completed. These dates and plans remain as stated in the company’s report, while no implementation outcomes have yet been announced.